Key figures as at September 30, 2016

 

Cash, cash equivalents and financial assets*

€239.6m

* Including current and non-current

Financial debt

€5.6m


Staff

143 employees, 3/4 of whom are dedicated to R&D


Portfolio

7 programs in development:

  • 3 programs in clinical trials including one licensed to Bristol-Myers Squibb and one partnered with AstraZeneca
  • 4 proprietary preclinical programs

See FY financial results for 2015

See HY financial results for 2016